(Total Views: 569)
Posted On: 08/15/2022 10:26:41 PM
Post# of 154719
also in the news today gsk will not take their option with ideaya ide397 re tumors.
"The resulting MAT2A inhibitor is called IDE397. But in a second-quarter earnings this morning, Ideaya revealed that GSK has waived its rights to exercise an option for the exclusive license to IDE39 or any other MAT2A-targeting compounds Ideaya will work on."
'
"The resulting MAT2A inhibitor is called IDE397. But in a second-quarter earnings this morning, Ideaya revealed that GSK has waived its rights to exercise an option for the exclusive license to IDE39 or any other MAT2A-targeting compounds Ideaya will work on."
'
(2)
(0)
